Judith S. Sebolt-Leopold, PhD
Co-director, Experimental Therapeutics Program
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Dr. Sebolt-Leopold is co-director of the Experimental Therapeutics Program at the University of Michigan Comprehensive Cancer Center. She is a principal investigator in the Translational Oncology Program at UMCCC where her laboratory is focused on the design of combination therapies targeting KRAS mutant cancers.
Before joining the University of Michigan in 2009, Dr. Sebolt-Leopold served as executive director of the Mechanistic and Target Biology Department at Pfizer Global R&D, Ann Arbor Laboratories. In this role, she led a group of over 100 scientists dedicated to early stage drug discovery activities, encompassing molecular pharmacology, assay development, and biomarker validation. She has 23 years of pharmaceutical industry experience and has led multiple research teams, resulting in the advancement of four oncology clinical candidates, including the first clinically tested MEK inhibitor. She has an international reputation in kinase inhibitor development and has pioneered and championed the viability of MEK inhibitors from early discovery through clinical development.
Dr. Sebolt-Leopold received her undergraduate degree from Wellesley College and a doctorate in biological sciences from Purdue University. She carried out postdoctoral studies in tumor biochemistry at the Indiana University School of Medicine under the mentorship of Dr. George Weber. She has a publication record that includes over 80 peer-reviewed articles, invited reviews, and issued patents.